Oliver Schoor
Paul Ehrlich Str. 15
Tuebingen, BW 72076, Germany
Tuebingen, BW 72076, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications
Autologous T cell therapy for PRAME+ advanced solid tumors in HLA-A*02+ patients: a phase 1 trial.
Journal: Nature medicine
Published: August 05, 2024
First-in-human dose escalation trial to evaluate the clinical safety and efficacy of an anti-MAGEA1 autologous TCR-transgenic T cell therapy in relapsed and refractory solid tumors.
Journal: Journal for immunotherapy of cancer
Published: June 21, 2024
Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer.
Journal: Cancer immunology research
Published: September 01, 2022
Quantitative immunopeptidomics reveals a tumor stroma-specific target for T cell therapy.
Journal: Science translational medicine
Published: August 31, 2022
Pitfalls in HLA Ligandomics-How to Catch a Li(e)gand.
Journal: Molecular & cellular proteomics : MCP
Published: December 17, 2020
Publisher Correction: Actively personalized vaccination trial for newly diagnosed glioblastoma.
Journal: Nature
Published: February 09, 2019
RNA editing derived epitopes function as cancer antigens to elicit immune responses.
Journal: Nature communications
Published: May 22, 2018
Actively personalized vaccination trial for newly diagnosed glioblastoma.
Journal: Nature
Published: May 08, 2018
A Cancer Research UK First Time in Human Phase I Trial of IMA950 (Novel Multipeptide Therapeutic Vaccine) in Patients with Newly Diagnosed Glioblastoma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: February 24, 2016
Natural HLA class I ligands from glioblastoma: extending the options for immunotherapy.
Journal: Journal of neuro-oncology
Published: June 13, 2012
Last Updated: 09/26/2026